HK1153136A1 - - Google Patents

Info

Publication number
HK1153136A1
HK1153136A1 HK11107242.8A HK11107242A HK1153136A1 HK 1153136 A1 HK1153136 A1 HK 1153136A1 HK 11107242 A HK11107242 A HK 11107242A HK 1153136 A1 HK1153136 A1 HK 1153136A1
Authority
HK
Hong Kong
Prior art keywords
hydroxybenzoyl
butanoate
insulin
chloro
amorphous
Prior art date
Application number
HK11107242.8A
Other languages
English (en)
Inventor
Satej Bhandarkar
Shingai Majuru
Halina Leuchyk
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of HK1153136A1 publication Critical patent/HK1153136A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK11107242.8A 2002-01-09 2011-07-12 HK1153136A1 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34761002P 2002-01-09 2002-01-09

Publications (1)

Publication Number Publication Date
HK1153136A1 true HK1153136A1 (xx) 2012-03-23

Family

ID=23364463

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11107242.8A HK1153136A1 (xx) 2002-01-09 2011-07-12

Country Status (8)

Country Link
US (5) US7227033B2 (xx)
EP (2) EP2272501B1 (xx)
JP (1) JP4508646B2 (xx)
AU (1) AU2003223158B2 (xx)
CA (1) CA2471144C (xx)
ES (2) ES2664189T3 (xx)
HK (1) HK1153136A1 (xx)
WO (1) WO2003057650A2 (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4508646B2 (ja) * 2002-01-09 2010-07-21 エミスフェアー・テクノロジーズ・インク 4−[(4−クロロ−2−ヒドロキシベンゾイル)アミノ]ブタン酸ナトリウムの多形体
JP5452843B2 (ja) * 2003-01-06 2014-03-26 エミスフィアー テクノロジーズ インコーポレイテッド 夜間の経口インスリン治療
US20050203001A1 (en) * 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
NZ551196A (en) * 2004-05-14 2010-08-27 Emisphere Tech Inc Compounds and compositions for delivering active agents
MXPA06013295A (es) 2004-05-19 2007-02-22 Emisphere Tech Inc Formulaciones de aciclovir.
MXPA06013384A (es) 2004-05-19 2007-03-01 Emisphere Tech Inc Formulaciones topicas de cromolin.
WO2006017541A2 (en) * 2004-08-03 2006-02-16 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
GB0427603D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
MX2007008082A (es) * 2004-12-29 2007-09-05 Emisphere Tech Inc Formulaciones farmaceuticas de sales de galio.
US8110547B2 (en) 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
US8030271B2 (en) 2005-07-05 2011-10-04 Emisphere Technologies, Inc. Compositions and methods for buccal delivery of human growth hormone
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
WO2008003050A2 (en) * 2006-06-28 2008-01-03 Emisphere Technologies, Inc. Gallium nitrate formulations
JP5985985B2 (ja) 2009-08-03 2016-09-06 エミスフィアー テクノロジーズ インコーポレイテッドEmisphere Technologies,Inc. 胃腸への影響が減少した即効型ナプロキセン組成物
BR112015006176B1 (pt) 2012-09-21 2023-04-18 Intensity Therapeutics, Inc Uso de um agente terapêutico e de um agente de intensificação de permeação intracelular
MX360107B (es) 2012-11-13 2018-10-23 Adocia Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido.
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) * 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
CN113167568B (zh) * 2018-11-29 2023-04-28 日本电气方案创新株式会社 坐标计算装置、坐标计算方法和计算机可读记录介质
CN111925298B (zh) * 2020-09-02 2023-05-30 无锡紫杉药业有限公司 一种4-cnab及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5811856B2 (ja) * 1975-07-14 1983-03-04 中外製薬株式会社 2 4− ビス (2’ − アセトキシベンズアミド ) アンソクコウサンノ イケイケツシヨウノ セイゾウホウ
JPS5312417A (en) * 1976-07-20 1978-02-03 Sumitomo Chem Co Ltd Preparation of amorphous d rugs
US4421685A (en) 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
DE3266360D1 (en) * 1981-06-16 1985-10-24 Choay Sa Medicines containing as active ingredients compounds of the arylbenzenesulfonamide-type, and processes for their preparation
USRE35862E (en) 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5443841A (en) 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US5583020A (en) * 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
US5401516A (en) 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1025840B1 (en) 1993-04-22 2005-06-29 Emisphere Technologies, Inc. Oral drug compositions
US5534488A (en) 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
JP3462895B2 (ja) * 1993-11-05 2003-11-05 三井化学株式会社 安息香酸誘導体の多価金属塩の製造方法
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
US5776888A (en) 1997-02-07 1998-07-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1998034632A1 (en) 1997-02-07 1998-08-13 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
GB9808896D0 (en) * 1998-04-25 1998-06-24 Smithkline Beecham Plc Novel compound
PL200710B1 (pl) * 1998-06-19 2009-01-30 Teijin Pharma Ltd Polimorfy kwasu 2-(3-cyjano-4-izobutyloksyfenylo)-4-metylo-5-tiazolokarboksylowego i sposób ich wytwarzania
HUP0103188A2 (hu) 1998-08-07 2001-12-28 Emisphere Technologies, Inc. Vegyületek és készítmények hatóanyagok célbajuttatására
CN1338924A (zh) 1999-01-08 2002-03-06 艾米斯菲尔技术有限公司 聚合物输送剂和输送剂化合物
DE19903275A1 (de) 1999-01-28 2000-08-03 Merck Patent Gmbh Lyophilisate mit verbesserter Rekonstituierbarkeit
ATE309197T1 (de) 1999-02-05 2005-11-15 Emisphere Tech Inc Verfahren zur herstellung alkylierter salicylamide
EP1163209A4 (en) 1999-02-26 2004-12-29 Emisphere Tech Inc COMPOUNDS AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS
DE60017888T2 (de) * 1999-04-05 2006-01-19 Emisphere Technologies, Inc. Dinatrium-salze, monohydrate und ethanol-solvate
GB9923934D0 (en) * 1999-10-08 1999-12-08 Smithkline Beecham Plc Novel pharmaceutical
GB9923933D0 (en) * 1999-10-08 1999-12-08 Smithkline Beecham Lab Novel pharmaceutical
NZ530450A (en) 1999-11-05 2004-06-25 Emisphere Tech Inc Phenoxy carboxylic acid compounds and compositions for delivering active agents
JP2001240581A (ja) * 2000-02-29 2001-09-04 Senju Pharmaceut Co Ltd アミノベンズアミド誘導体およびその用途
JP4799794B2 (ja) 2000-03-21 2011-10-26 エミスフェアー・テクノロジーズ・インク ジカルボキシル化中間体を介してアルキル化サリチルアミドを調製する方法。
MXPA02012855A (es) 2000-06-29 2004-04-20 Emisphere Tech Inc Compuestos y composiciones para suministrar agentes activos.
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
JP4508646B2 (ja) 2002-01-09 2010-07-21 エミスフェアー・テクノロジーズ・インク 4−[(4−クロロ−2−ヒドロキシベンゾイル)アミノ]ブタン酸ナトリウムの多形体

Also Published As

Publication number Publication date
CA2471144A1 (en) 2003-07-17
US7227033B2 (en) 2007-06-05
US20090010882A1 (en) 2009-01-08
US20050272639A1 (en) 2005-12-08
US7208178B2 (en) 2007-04-24
JP2005520803A (ja) 2005-07-14
US20080033204A1 (en) 2008-02-07
US7420085B2 (en) 2008-09-02
AU2003223158B2 (en) 2008-01-17
US7462368B2 (en) 2008-12-09
ES2412306T3 (es) 2013-07-11
WO2003057650A2 (en) 2003-07-17
AU2003223158A1 (en) 2003-07-24
EP1469827A2 (en) 2004-10-27
JP4508646B2 (ja) 2010-07-21
ES2664189T3 (es) 2018-04-18
US7893297B2 (en) 2011-02-22
EP1469827A4 (en) 2006-08-16
US20070161708A1 (en) 2007-07-12
US20050250852A1 (en) 2005-11-10
WO2003057650A3 (en) 2003-10-16
EP2272501B1 (en) 2013-03-20
EP1469827B1 (en) 2017-12-27
CA2471144C (en) 2011-06-07
EP2272501A1 (en) 2011-01-12

Similar Documents

Publication Publication Date Title
HK1153136A1 (xx)
HRP20040710A2 (en) Antibody-containing solution pharmaceuticals
AU2003243096A1 (en) NOVEL PURINE- OR PYRROLOL(2,3-d)PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY
ZA200502406B (en) Sustained released delivery of amphetamine salts.
HK1078568A1 (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
IL157254A0 (en) N-substituted nonaryl-heterocyclic nmda/mr2b antagonists
EP1572101A3 (en) Disease treatment via antimicrobial peptide inhibitors
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
HK1076816A1 (xx)
IL169184A0 (en) Aromatic compounds as anti-inflammatory, immunomdulatory and anti-proliferatory agents
AU2003212310A1 (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
MXPA04006041A (es) Antivirales de piridoquinoxalina.
EP1552826A4 (en) AMINO ACID COMPOSITIONS TO IMPROVE CENTRAL FUNCTIONS
AU2003249535A1 (en) 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
WO2005065047A3 (en) Stable oral composition containing desloratadine
EP1549346A4 (en) MODIFIED RECOMBINANT CELLS (ARCS) FOR THE PRODUCTION AND DISTRIBUTION OF ANTIVIRAL AGENTS, ADJUVANTIES AND VACCINE ACCELERATORS
EP1568704A4 (en) NOVEL 2 ', 5'-OLIGOADENIC ACID ANALOG
GB2416123A (en) Stable carprofen composition
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
AU2003209437A1 (en) Amine oxides as perfume solubility agents
AU2003250465A1 (en) 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors
AU2003257407A1 (en) S-(+)-3-{1-(2-(2,3-dihydro-1h-indol-3-yl)ethyl)-3,6-dihydro-2h-pyridin-4-yl}-6-chloro-1h-indole and acid addition salts thereof
WO2004056306A3 (de) Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen
EP1486208A4 (en) NEW PREVENTIVE TREATMENT AGAINST INFECTIONS
WO2004051549A8 (en) Active agent delivery method

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180109